Our site uses cookies, view our cookie policy. To view the site without this banner, you must accept our cookie usage.

Photograph of Dr. Christopher Boos

Our Staff

Dr Christopher J Boos
MBBS Dip IMC RCS MRCP MD

GMC number: 4106845

Specialty

Cardiology and General Internal Medicine

Subspecialty

Heart Failure Specialist 

Cardiac Device Specialist (including cardiac resynchronisation therapy [CRT] and implantable cardiac defibrillators [ICD])

Sports Cardiology and cardiopulmonary exercise testing (CPX, CPET, CPEX) and Medico legal work

 

Other interests: atrial fibrillation, high altitude medicine, breathlessness and cardiomyopathies

Qualifications

  • MB BS, St Mary's Hospital Medical School, London, 1994

  • Dip IMC RCS Royal College of Surgeons of Edinburgh, 1997

  • MD - Doctor of Medicine, University of Birmingham, 2007

  • FRCP, Royal College of Physicians of London, 2011

Background

After qualifying at St Mary's Hospital in London in 1994, I undertook junior hospital appointments in London (St Mary's Hospital, Royal London and Royal Brompton Hospitals) and Portsmouth (Queen Alexandra, St Mary's and Haslar Hospitals). Thereafter, I commenced my Cardiology training initially in the Wessex region where I worked in Salisbury (one year), Portsmouth (two years) and Southampton General Hospitals (one year) respectively. I then transferred to the Birmingham Deanery after to do a two year Research Doctorate (MD) at City Hospital. Subsequently, I then completed my final 18 months of Cardiology training at University Hospital Birmingham, prior to moving to Poole as a Consultant Cardiologist.

My current NHS employment is at both Poole and the Royal Bournemouth with additional private sessions at these hospitals and at the Harbour Hospital in Poole.

Publications

Original Articles

  • Boos C, Wilbourne G, Clarke E et al. Higher energy monophasic direct current cardioversion for persistent atrial fibrillation: is it time to start at 360 joules? Annals of Non Invasive Electrocardiology 2003;8:121-127.

  • Boos C and Croft A. Smoking rates in the staff of a military field hospital before and after wartime deployment. J R Soc Med 2004;97:20-22.

  • Boos C, Ritzema J and More R. Short burst oral amiodarone improves cardioversion success rates for patients in persistent atrial fibrillation. Heart 2004 2004;90:1063-4.

  • Boos CJ, Gough S, Wheater M et al. The Effects of Transvenous Pacing on Cardiac Troponin Release. Pacing Clin Electrophysiol 2004;27:1264-1268.

  • Bailey MS, Boos CJ, Vautier G et al. Gastroenteritis outbreak in British troops, Iraq. Emerg Infect Dis 2005;11:1625-8.

  • Boos CJ, Lane DA, Kang D et al. Temporal and venepuncture-related decline in Circulating Endothelial Cell capture from mixed venous blood. J Thromb Thrombolysis 2006;22:125-31.

  • Goon PKY, Boos CJ, Stonelake PS et al. Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads:  a methodological comparison. Thromb Haemostas 2006;96:45-52.

  • Boos CJ, Jaumdally RJ, Macfayden RJ et al. Circulating endothelial cells and von Willebrand factor as indices of endothelial damage/dysfunction in coronary artery disease: a comparison of central vs peripheral levels and effects of coronary angioplasty. J Thromb Haemost 2007;5:630-2. 

  • Boos CJ, Beevers G, Lip GYH. Assessment of platelet activation indices using the ADVIATM120 amongst ‘high risk’ patients with hypertension. Ann Med 2007;39:72-8. 

  • Boos CJ, Mayr FB, Lip GY et al. Endotoxemia enhances circulating endothelial cells in humans. J Thromb Haemost 2006;4:2509-11.

  • Boos CJ, Soor SK, Kang D et al. Relationship between Circulating Endothelial Cells and the predicted risk of Cardiovascular Events in Acute Coronary Syndromes. European Heart Journal 2007;28:1092-101. 

  • Goon PK, Watson T, Shantsila E, Boos CJ and Lip GY. Standardization of circulating endothelial cell enumeration by the use of human umbilical vein endothelial cells. J Thromb Haemost 2007;5:870-2. 

  • Boos CJ, Balakrishnan B and Lip GY. The effects of exercise stress testing on soluble E-selectin, von Willebrand factor, and circulating endothelial cells as indices of endothelial damage/dysfunction. Ann Med 2008;40:66-73. 

  • Boos CJ, Lip GY and Jilma B. Endotoxemia, inflammation, and atrial fibrillation. Am J Cardiol 2007;100:986-8. 

  • Boos CJ, Balakrishnan B and Lip GY. The effects of coronary artery disease severity on time-dependent change in platelet activation indices in stored whole blood. J Thromb Thrombolysis 2008;25:135-40. 

  • Boos CJ, Lane DA, Karpha M et al. Circulating endothelial cells, arterial stiffness and cardiovascular risk stratification in hypertension. Chest 2007;132:1540-7. 

  • Boos CJ, Balakrishnan B, Jessani S, Blann AD, Lip GY. Effects of percutaneous coronary intervention on peripheral venous blood circulating endothelial cells and plasma indices of endothelial damage/dysfunction. Chest 2007;132:1920-6. 

  • Boos CJ, Balakrishnan B, Blann AD, Lip GY. The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis. J Thromb Haemos. 2008;6:1841-50. 

  • Boos CJ, Wheble GA, Campbell MJ, Tabner KC, Woods DR.Self-administration of exercise and dietary supplements in deployed British military personnel during Operation TELIC 13. J R Army Med Corps 2010;156:32-6. 

  • Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, Boos CJ, Xing W, Egan C, Peto T, Bunce C, Leslie RD, Hykin PG. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078.

  • Idriss NK, Lip GY, Balakrishnan B, Jaumdally R, Boos CJ, Blann AD. Plasma haemoxygenase-1 in coronary artery disease. A comparison with angiogenin, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor. Thromb Haemost 2010;104:1029-37.

 

Review Articles

  • Boos C and More R. Rate control in atrial fibrillation. Clinical Medicine 2003;3:291-2.

  • Boos C and More R. Management of Persistent Atrial Fibrillation in the Older Patient. Geriatric Medicine 2003;33:51-7.

  • Carlsson J and Boos C. Confounding factors in rate versus rhythm control trials in patients with atrial fibrillation: Lessons from the Strategies of Treatment of Atrial Fibrillation (STAF) Pilot Study. Card Electrophysiol Rev 2003;7:122-6.

  • Boos C, Carlsson J and More R. Rate or rhythm control in persistent atrial fibrillation, Quarterly Journal of Medicine 2003;96:881-92.

  • Boos CJ and More R. Anticoagulation for non-valvular atrial fibrillation - towards a new beginning with ximelagatran. Curr Control Trials Cardiovasc Med 2004;5:3.

  • Boos CJ and Lip GYK. Novel therapies for the prevention of stroke. Expert Opin Investig Drugs 2004;13:1615-30.

  • Boos CJ ACE Cardiovascular protection. More HOPE for EUROPA Med Sci Monit 2004;10:SR23-28.

  • Boos CJ, Hinton A and Lip GYH Ximelagatran: a clinical perspective. Eur J Intern Med 2005; 16:267-78.

  • Boos CJ and Lip GYH Blood clotting, inflammation, and thrombosis in cardiovascular events: perspectives. Front Biosc 2006;11:328-36.

  • Boos CJ and Lip GYH Ximelagatran for stroke prevention in atrial fibrillation. Expert Rev Cardiovasc Ther 2005;3:551-63.

  • Goon PKY, Boos CJ and Lip GYH Circulating Endothelial Cells: markers of vascular dysfunction. Clin Lab 2005;51:531-8.

  • Boos CJ and Lip GYH Is hypertension an inflammatory process. Curr Pharm Des 2006;12:1623-1635.

  • Boos CJ and Lip GYH Antithrombotic treatment in atrial fibrillation. Heart 2006;92:155-61.

  • Boos CJ, Anderson RA and Lip GYH Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006;27:136-49.

  • Boos CJ and Lip GYH Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. J Hum Hypertens 2005;19:855-9

  • Goon PKY, Boos CJ and Lip GYH Circulating endothelial cells in malignant disease. Future Oncology 2005;1:813-20.

  • Goon PKY, Boos CJ and Lip GYH Circulating endothelial cells and circulating endothelial progenitor cells in cancer. Neoplasia 2006;8:79-88.

  • Boos CJ, Lip GY and Blann AD Circulating endothelial cells in cardiovascular disease. J Am Coll Cardiol 2006;48:1538-47.

  • Boos CJ and Lip GY Assessment of mean platelet volume in coronary artery disease - What does it mean? Thromb Res 2007;120:11-3.

  • Boos CJ, Lane D and Lip GYH Management of chronic atrial fibrillation. Clin Evidence (BMJ) 2007

  • Kakar P, Boos CJ and Lip GY Management of atrial fibrillation. Vasc Health Risk Manag 2007;3:109-16.

  • Boos CJ, Blann AD and Lip GY. Assessment of endothelial damage/dysfunction: a focus on circulating endothelial cells. Methods Mol Med 2007;139:211-24.

  • Lip GYH, Boos CJ Antithrombotic treatment in atrial fibrillation. Postgrad Med J 2008;84:252-8.

  • Boos CJ, Blann AD, Lip GY Assessment of endothelial damage/dysfunction: a focus on circulating endothelial cells. Methods Mol Med 2007;139:211.

  •  

    Boos CJ, Cox AT. Cardiology. J R Army Med Corps 2010;156:172-5.

  •  

    Woods DR, Boos C, Roberts PR. Cardiac arrhythmias at high altitude. J R Army Med Corps 2011;157:59-62

     

     

     

Editorials

  • Boos C, Carlsson J and More R Persistent atrial fibrillation. Rate control or rhythm control. Rate control is not inferior to rhythm control. BMJ 2003;326:1411-12.

  • Boos CJ and Dawes M ACE cardiovascular protection: EUROPA versus HOPE. Cardiovascular Drugs and Therapy 2004;18:179-180.

  • Boos CJ and Lip GYH Elevated high-sensitive C-reactive protein, large arterial stiffness and atherosclerosis: a relationship between inflammation and hypertension? J Hum Hypertens 2005;19:511-3.

  • Boos CJ and Lip GYH The role of inflammation in atrial fibrillation. Int J Clin Pract 2005;59:870-2.

  • Lip GYH and Boos CJ Ethnic differences in arterial responses, inflammation, and metabolic profiles: possible insights into ethnic differences in cardiovascular disease and stroke. Arterioscler Thromb Vasc Biol 2005;25:2240-2.

  • Boos CJ and Lip GYH Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events. Arterioscler Thromb Vasc Biol 2006;26:e18.

  • Boos CJ, Goon PKY and Lip GYH The endothelium, inflammation and coagulation in sepsis. Clin Pharmacol Ther 2006;79:20-2.

  • Boos CJ, Goon PK and Lip GY Endothelial progenitor cells in the vascular pathophysiology of hypertension: arterial stiffness, ageing and more. J Hum Hypertens 2006;20:475-7.

  • Boos CJ and Lip GYH Ximelagatran – a eulogy. Throm Res 2006;118:301-4.

  • Lane DA, Boos CJ and Lip GYH Anticoagulation control with vitamin K antagonists- how well are we doing? Chest 2006;129:1122-4.

  • Boos CJ and Lip GYH Urotensin and cardiovascular risk among patients with end-stage renal disease: fact or fiction? Am J Hypertens 2006;19:511-2.

  • Boos CJ and Lip GY Platelet activation and cardiovascular outcomes in acute coronary syndromes. J Thromb Haemost 2006;4:2542-3.

  • Boos CJ, Lip GY C-reactive protein and lone atrial fibrillation: potential confounders.Am J Cardiol 2006;98:991-2.

  • Boos CJ and Lip GY. Inflammation and atrial fibrillation: cause or effect? Heart 2008;94:133-4.

     

Case Reports

  • Boos CJ Keloid scarring in a soldier secondary to military cap badge branding. Update 1997;654.

  • Boos C and Matfin G Klinefelter's Syndrome manifesting as an acute pulmonary embolus in a 52 year old man. Endocrine Practice 2002;8:68-9.

  • Boos C, Rumsby G and Matfin G Multiple tumors associated with late onset congenital adrenal hyperplasia due to aberrant splicing of adrenal 21-hydroxylase gene. Endocrine Practice 2003;8:470-3.

  • Boos C, Dawes M, Jones R et al T. Danazol treatment and acute myocardial infarction. Journal of Obstetrics and Gynaecology 2003;23:327-8.

  • Boos C, Allen P, More R et al Fever six weeks after trauma. Journal of the Royal Society of Medicine 2003;96:187-8.

  • CJ Boos, P Flies, M Dawes et al Shortness of breath in an obese young man. Journal of Academic Physician Assistants 2003;3:2.

  • Boos CJ, Daneshvar C, Hinton A et al An unusual case of chronic meningitis. BMC Fam Pract 2004;5:21.

  • Boos CJ, Calver AL, Moors A et al Uterine artery embolisation in the setting of acute submassive pulmonary embolism. BJOG 2005;112:1440-2.

  • Boos CJ, Khan Y and Throne S An unusual case of misdiagnosed ventricular tachycardia. Emerg Med J 2008;25:173-4.

  • Boos CJ, Bentall AJ, Marshall HJ A technique to overcome high defibrillation thresholds for an implantable cardioverter defibrillator Cardiol Young 2009;19:291.

  • Boos CJ, Martin U, Cherry RC, Marshall HJ. Dangerous Sanwiches. Lancet 2008;372:2164.

  • Boos CJ, White SH, Bland SA, McAllister PD.  Dietary supplements and military operations: caution is advised.  J R Army Med Corp 2010;156:41-3.

  • White SH, Dickson S, Colman T, Hoque F, Boos CJ. Back pain in a Bangladeshi worker in Iraq. J R Army Med Corps 2010;156:44-6 .

     

Letters

  • Boos CJ Present treatment options for atrial fibrillation. Postgrad Med J 2003;79:604.

  • Boos CJ Atrial fibrillation. Cleve Clin J Med 2003;70:998.

  • Boos CJ Oral anticoagulation and stroke in atrial fibrillation. N Engl J Med 2003;349:2360-1.

  • Boos CJ The EUROPA trial. Lancet 2003;362:1935.

  • Boos CJ Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004;25:1761.

  • Boos CJ, Lip GYH Biomarkers in atrial fibrillation: further observations on biologic plausibility, cause and effect Journal of Thrombosis and Thrombolysis 2005;20:189-90.

  • Boos CJ, Lip GYH Prevention of Atrial fibrillation by Angiotensin-Converting-Enzyme inhibitors and Angiotensin II receptor blockers: some pathophysiological insights. J Am Coll Cardio 2006;47:889-90.

  • Boos CJ, Goon PKY and Lip GYH Circulating endothelial progenitor cells. N Engl J Med 2005;353:2613.

  • Boos CJ and Lip GYH Assessment of Hemostatic Risk Factors in Predicting Arterial thrombotic Events.  ATVB 2006;26:e18.

  • Boos CJ and Lip GYH The role of inflammation in atrial fibrillation: Increasing Evidence in support of a novel concept. In J Clin Pract 2006; 60:497-8.

  • Boos CJ and Lip GYH Is atrial fibrillation an inflammatory disorder?  Responses and clarifications. European Heart Journal 2006;27:136-49.

  • Boos CJ and Marshall HJ Risk of thromboembolism and bleeding with short-term interruption of anticoagulant therapy. Arch Intern Med 2008;168:1932.

  • Gorman S, Boos C Ivabradine in heart failure: what about digoxin? Lancet 2008;372:2113.

Book Chapters

  • Boos CJ and Lip GYH Assessment of endothelial damage/dysfunction: a focus on circulating endothelial cells. Vascular Biology Protocols 2006.

  • Boos CJ and Lip GYH Insights into novel anticoagulants. Thrombosis Molecular Mechanisms of Disease 2006.